Cambridge Trust’s Haemonetics HAE Stock Holding History

Cambridge Trust’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-51	Closed	-$3K	–	894
2022 Q1	$3K	Sell	51 -132	-72%	-$7.18K	﹤0.01%	849
2021 Q4	$10K	Buy	+183	New	+$11.2K	﹤0.01%	807

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

LCP

LGT Capital Partners Pfaeffikon, Switzerland $1.88B AUM 20.37% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cambridge Trust's HAE Position: Q2 2022 in Review

Cambridge Trust sold out of Haemonetics (HAE) in Q2 2022, closing a stake of 51 shares — an estimated $3K sold.

Cambridge Trust first reported a position in HAE in Q4 2021 and held it in 2 quarters. The position peaked at $10K in Q4 2021. 241 funds tracked by Wall St. Rank hold HAE as of Q2 2022.

Cambridge Trust reported no remaining Haemonetics position as of Q2 2022 after selling out during the quarter.
Cambridge Trust sold 51 Haemonetics shares in Q2 2022, an estimated $3K.
Cambridge Trust first reported a position in Haemonetics in Q4 2021 and held it in 2 quarters.
Cambridge Trust's Haemonetics position peaked at $10K in Q4 2021.
241 funds tracked by Wall St. Rank held Haemonetics as of Q2 2022.

Based on Cambridge Trust's 13F filing for Q2 2022, filed 16 Aug 2022.